Literature DB >> 32387234

Indole alkaloids from leaves of Alstonia scholaris (L.) R. Br. protect against emphysema in mice.

Yun-Li Zhao1, Zi-Feng Yang2, Bai-Fen Wu3, Jian-Hua Shang4, Ya-Ping Liu4, Xin-Hua Wang5, Xiao-Dong Luo6.   

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE: Alstonia scholaris (L.) R. Br. (Apocynaceae) is a medicinal plant in China traditionally used to treat pulmonary diseases, including bronchitis, whooping cough, asthma and chronic obstructive pulmonary disease. AIM OF THE STUDY: To provide experimental data supporting clinical adaptation of total indole alkaloids ( TA) from A. scholaris leaves for treating emphysema.
MATERIALS AND METHODS: An emphysema model was induced by a single intratracheal instillation of porcine pancreatic elastase followed by administration of TA and four main alkaloid components (scholaricine, 19-epischolaricine, vallesamine, and picrinine) for 30 consecutive days. Cytokine levels, histopathological parameters and protein expression in lung tissues were examined.
RESULTS: Administering the TA, picrinine, scholaricine, 19-epischolaricine and vallesamine for 30 days effectively inhibited inflammatory cell accumulation and invasion in the lung tissue and relieved pulmonary tissue injury. Oxygen saturation was enhanced, and interleukin (IL)-1β, monocyte-chemo attractive peptide 1, IL-11, matrix metalloproteinase-12, transforming growth factor-β and vascular endothelial growth factor levels were significantly reduced, likely by suppressing overactivation of alveolar macrophages and pulmonary fibrosis. The elastin content was markedly elevated, and fibronectin was reduced. Bcl-2 expression was significantly increased, and nuclear factor-κB and β-catenin levels were decreased.
CONCLUSIONS: TA can be potentially used as an effective novel drug for pulmonary emphysema and exerts its effects through not only inhibiting inflammation of the airway wall and airflow resistance but also promoting lung elastic recoil and protease/anti-protease balance.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Alstonia scholaris leaf; Apoptosis; Indole alkaloids; Inflammation; Protease/antiproteinase balance; Pulmonary emphysema

Mesh:

Substances:

Year:  2020        PMID: 32387234     DOI: 10.1016/j.jep.2020.112949

Source DB:  PubMed          Journal:  J Ethnopharmacol        ISSN: 0378-8741            Impact factor:   4.360


  5 in total

1.  Meleagrin Isolated from the Red Sea Fungus Penicillium chrysogenum Protects against Bleomycin-Induced Pulmonary Fibrosis in Mice.

Authors:  Sameh S Elhady; Marwa S Goda; Eman T Mehanna; Mahmoud A Elfaky; Abdulrahman E Koshak; Ahmad O Noor; Hanin A Bogari; Rania T Malatani; Reda F A Abdelhameed; Alaa S Wahba
Journal:  Biomedicines       Date:  2022-05-18

2.  Anti-microbial Effects In Vitro and In Vivo of Alstonia scholaris.

Authors:  Yun-Li Zhao; Zhong-Ping Gou; Jian-Hua Shang; Wan-Yi Li; Yu Kuang; Ming-Yuan Li; Xiao-Dong Luo
Journal:  Nat Prod Bioprospect       Date:  2021-01-03

3.  The safety and tolerability of alkaloids from Alstonia scholaris leaves in healthy Chinese volunteers: a single-centre, randomized, double-blind, placebo-controlled phase I clinical trial.

Authors:  Zhong-Ping Gou; Yun-Li Zhao; Lin-Ling Zou; Ying Wang; Shi-Qing Shu; Xiao-Hong Zhu; Li Zheng; Qi Shen; Zhu Luo; Jia Miao; Yong-Sheng Wang; Xiao-Dong Luo; Ping Feng
Journal:  Pharm Biol       Date:  2021-12       Impact factor: 3.503

Review 4.  Indole-Based Small Molecules as Potential Therapeutic Agents for the Treatment of Fibrosis.

Authors:  Rui Qin; Qian Zhao; Bo Han; Hong-Ping Zhu; Cheng Peng; Gu Zhan; Wei Huang
Journal:  Front Pharmacol       Date:  2022-02-16       Impact factor: 5.810

5.  Indole alkaloids of Alstonia scholaris (L.) R. Br. alleviated nonalcoholic fatty liver disease in mice fed with high-fat diet.

Authors:  Shui-Fen Sun; Hui-Jie Zhong; Yun-Li Zhao; Xiu-Ying Ma; Jin-Bo Luo; Ling Zhu; Yu-Ting Zhang; Wen-Xue Wang; Xiao-Dong Luo; Jia-Wei Geng
Journal:  Nat Prod Bioprospect       Date:  2022-04-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.